Capitol police what you knew donald trump had planned . You were in those meetings at the white house. Thats former congresswoman liz cheney calling out fellow republican jim jordan whos now a top candidate to replace Kevin Mccarthy as house speaker. Well have the latest on that race in just a moment. Meanwhile, donald trump could also be on capitol hill next week to endorse jordans bid for speaker. This would be trumps first visit to the capitol since the insurrection he inspired. And this comes as theres an alarming new report from the New York Times on trumps handling of nuclear secrets. Good morning and welcome to Way Too Early on this friday, october 6th. We made it to friday just barely. Im jonathan lemire. Thanks for starting your day with us. And well begin this morning with the race for the speaker of the house. Currently only two announced candidates are in the running. House Judiciary Committee House Judiciary Chair jim jordan and majority leader Steve Scalise. Jordan is alr
Damien Conover and Rebecca Springer: We Are in a Healthcare Consumerization Moment Right Now
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Anti-Obesity Drugs Global Strategic Business Report 2024:
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
U.S.-based Eli Lilly and Denmark's Novo Nordisk have struck gold with their weight-loss drugs, sending their shares to stratospheric levels and putting them on par with some high-growth tech stocks. Retail and institutional investors alike have flocked to the two stocks in the past year, as they bet on explosive demand for the companies' obesity drugs, called GLP-1 agonists, in a market that some analysts expect could breach $100 billion. Lilly shares trade 56.17 times the earnings estimates for the next 12 months, while Novo has a price-to-earnings (PE) multiple of 35.84, according to LSEG data.